Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate 280 mg Once Weekly in Paget's Disease of Bone
NCT00480662Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Oct 2001
- Primary completion
- Oct 2002
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of alendronate in Paget's disease of bone, sponsored by Organon & Co.. Started Oct 2001; status: completed.
02
Drugs
alendronate
03
Conditions
Paget's disease of bone
Beyond the preview
Go deeper on NCT00480662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480662.